전립선비대증 환자에서 Tolterodine과 Oxybutynin이 야간뇨에 미치는 효과
The Effect of Tolterodine and Oxybutyninin on Nocturia in Patients with Benign Prostatic Hyperplasia
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Nocturia has been one of the most bothersome symptoms in benign prostatic hyperplasia (BPH) patients. Therefore, the authors evaluated the effect of tolterodine and oxybutyninin on nocturia in BPH patients. Materials and Methods: From September 2006 to March 2007, 82 patients who presented over than 2 in nocturnal bladder capacity index (NCBI) in spite of having alpha blockers for 6 months were enrolled. Group I (n=38) took alpha blocker with tolterodine, group II (n=44) took alpha blocker with oxybutynin. The number of their nocturia episodes was separately evaluated by the time before and after the medication. The complications were assessed using a questionnaire. Results: The number of nocturia episodes decreased by at least 1 in 68.4% (26/38), 84.1% (37/44) of patients in group I, II, respectively, and decreased by 2 or more, 1 and were unchanged or increased were 36.8, 31.6, 31.6% in group I patients and 45.5, 38.6, 15.9% in group II patients, respectively. In baseline nocturia ≥6 group, the nocturia decreased by 1 or more in 66.7%, 77.8% in group I, II, respectively. Adverse events, including dry mouth, dizziness, headache, etc, occurred in 21.1% (8/38) in group I and 27.3% (12/44) in group II patients. The complications between two groups showed no significant differences. Conclusions: Alpha blockers with tolterodine or oxybutynin can be effectively combined as a treatment option for patients with BPH complaining of unresolved nocturia. (J Korean Continence Soc 2009;13: 23-29)
Abstract
Purpose: Nocturia has been one of the most bothersome symptoms in benign prostatic hyperplasia (BPH) patients. Therefore, the authors evaluated the effect of tolterodine and oxybutyninin on nocturia in BPH patients. Materials and Methods: From September 2006 to March 2007, 82 patients who presented over than 2 in nocturnal bladder capacity index (NCBI) in spite of having alpha blockers for 6 months were enrolled. Group I (n=38) took alpha blocker with tolterodine, group II (n=44) took alpha blocker with oxybutynin. The number of their nocturia episodes was separately evaluated by the time before and after the medication. The complications were assessed using a questionnaire. Results: The number of nocturia episodes decreased by at least 1 in 68.4% (26/38), 84.1% (37/44) of patients in group I, II, respectively, and decreased by 2 or more, 1 and were unchanged or increased were 36.8, 31.6, 31.6% in group I patients and 45.5, 38.6, 15.9% in group II patients, respectively. In baseline nocturia ≥6 group, the nocturia decreased by 1 or more in 66.7%, 77.8% in group I, II, respectively. Adverse events, including dry mouth, dizziness, headache, etc, occurred in 21.1% (8/38) in group I and 27.3% (12/44) in group II patients. The complications between two groups showed no significant differences. Conclusions: Alpha blockers with tolterodine or oxybutynin can be effectively combined as a treatment option for patients with BPH complaining of unresolved nocturia. (J Korean Continence Soc 2009;13: 23-29)
참고문헌 (28)
- Blanker MH, "Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men", J Urol, 164, pp.1201~1205 (2000)
- Bruskewitz RC, "3-year followup of urinary symptoms after transurethral resection of the prostate", J Urol, 136, pp.613~615 (1986)
- Johnson TM, "Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the department of Veterans Affairs Cooperative Study Trial", J Urol, 170, pp.145~148 (2003)
- Appell RA, "Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis", Urology, 50(6A), pp.90~96 (1997)
- Homma Y, "Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial", BJU Int, 92, pp.741~747 (2003)
- Kim ET, "The etiology and classification of nocturia in adults", Korean J Urol, 42, pp.1075~1079 (2001)
- Hetta J, "Mood alterations and sleep", Ann Clin Res, 17, pp.252~256 (1985)
- Lindberg E, "Sleep disturbances in a young adult population: can gender differences be explained by differences in psychological status?", Sleep, 20, pp.381~387 (1997)
- Fultz NH, "Epidemiology of urinary symptoms in the geriatric population", Urol Clin North Am, 23, pp.1~10 (1996)
- Chute CG, "The prevalence of prostatism: a populationbased survey of urinary symptoms", J Urol, 150, pp.85~89 (1993)
- Pressman MR, "A rarely recognized symptom of sleep apnea and other occult sleep disorders", Arch Intern Med, 156, pp.545~550 (1996)
- Asplund R, "Diurnal variation in the levels of antidiuretic hormone in the elderly", J Intern Med, 229, pp.131~134 (1991)
- 정재영, "전립선비대증 환자에서 알파 1(A) 아드레날린수용체 차단제 Tamsulosin의 역할: 하부요로증상 및 야간뇨에 대한 효과", Korean Journal of Urology, 47(1), pp.1~6 (2006), 대한비뇨기과학회
- Abrams P, "Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder", Br J Urol, 81, pp.801~810 (1998)
- Millard R, "Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity", J Urol, 161, pp.1551~1555 (1999)
- Andersson KE, "Antimuscarinics for treatment of overactive bladder", Lancet Neurol, 3, pp.46~53 (2004)
- Nilvebrant L, "Tissue distribution of tolterodine and its metabolites: low penetration into the central nervous system", Eur Urol, 37(2), pp.84~ (2000)
- Appell RA, "Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis", Urology, 50, pp.90~96 (1997)
- Drutz HP, "Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder", Int Urogynecol J Pelvic Floor Dysfunct, 10, pp.283~289 (1999)
- Kaplan SA, "Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia", J Urol, 174, pp.2273~2276 (2005)
- "J Urol", 2004, 917~
- Thompson IM, "Oxybutynin in bladder, spasm, neurogenic bladder and enuresis", Urology, 8, pp.452~454 (1976)
- Appel RA, "The clinical experience", Contemp Urol, 3, pp.60~67 (1991)
- Johnson TM II, "Effects of behavioral and drug therapy on nocturia in older incontinent women", J Am Geriatr Soc, 53, pp.846~850 (2005)
- Abrams P, "Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder", Br J Urol, 81, pp.801~810 (1998)
- Halaska M, "Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability", World J Urol, 20, pp.392~399 (2003)
- Zinner N, "Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder", World J Urol, 23, pp.248~252 (2005)
- Kaplan SA, "Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial", JAMA, 296, pp.2319~2328 (2006)